IXICO Plc (LON: IXI) has announced updates to client contracts expansion worth £2.4 million of study programmes with two large pharma clients.
- The company announced about the extension of £1.8 million contract to a Phase III study in Huntington's Disease (HD), previously announced in September 2018.
- Separately, a £0.6 million extension to a study programme in Progressive Supranuclear Palsy (PSP), previously announced in October 2019, too has been announced.
- On 23rd December 2019, at the time of writing, GMT 08:03 AM, IXI shares were trading at GBX 71.50, up by 1.00 points or 1.42% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.